ImmunityBio study showed positive T cell and antibody immune responses to its COVID-19 vaccine candidate
On Aug. 3, 2020, ImmunityBio announced positive preclinical results for its human Ad5 vaccine candidate that contains both the spike (S) and nucleocapsid (N) SARS-CoV-2 proteins (hAd5 S + N) for preventing COVID-19.
The results were published in bioRxiv.
Tags:
Source: Nantwest
Credit:
